As of 2025-04-22, the EV/EBITDA ratio of C4 Therapeutics Inc (CCCC) is -0.38. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CCCC's latest enterprise value is 43.89 mil USD. CCCC's TTM EBITDA according to its financial statements is -115.36 mil USD. Dividing these 2 quantities gives us the above CCCC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.8x - 12.4x | 11.1x |
| Forward P/E multiples | 19.5x - 41.2x | 30.4x |
| Fair Price | (30.91) - (19.37) | (32.90) |
| Upside | -2307.6% - -1483.4% | -2449.7% |
| Date | EV/EBITDA |
| 2025-04-21 | -0.38 |
| 2025-04-17 | -0.29 |
| 2025-04-16 | -0.20 |
| 2025-04-15 | -0.25 |
| 2025-04-14 | -0.28 |
| 2025-04-11 | -0.28 |
| 2025-04-10 | -0.26 |
| 2025-04-09 | -0.32 |
| 2025-04-08 | -0.26 |
| 2025-04-07 | -0.34 |
| 2025-04-04 | -0.33 |
| 2025-04-03 | -0.37 |
| 2025-04-02 | -0.45 |
| 2025-04-01 | -0.40 |
| 2025-03-31 | -0.50 |
| 2025-03-28 | -0.60 |
| 2025-03-27 | -0.65 |
| 2025-03-26 | -0.66 |
| 2025-03-25 | -0.86 |
| 2025-03-24 | -0.89 |
| 2025-03-21 | -0.82 |
| 2025-03-20 | -0.87 |
| 2025-03-19 | -0.84 |
| 2025-03-18 | -0.80 |
| 2025-03-17 | -0.81 |
| 2025-03-14 | -0.77 |
| 2025-03-13 | -0.76 |
| 2025-03-12 | -0.87 |
| 2025-03-11 | -0.78 |
| 2025-03-10 | -0.85 |
| 2025-03-07 | -0.97 |
| 2025-03-06 | -0.97 |
| 2025-03-05 | -1.01 |
| 2025-03-04 | -0.98 |
| 2025-03-03 | -1.00 |
| 2025-02-28 | -1.19 |
| 2025-02-27 | -1.12 |
| 2025-02-26 | -1.15 |
| 2025-02-25 | -1.24 |
| 2025-02-24 | -1.30 |
| 2025-02-21 | -1.37 |
| 2025-02-20 | -1.36 |
| 2025-02-19 | -1.37 |
| 2025-02-18 | -1.35 |
| 2025-02-14 | -1.48 |
| 2025-02-13 | -1.49 |
| 2025-02-12 | -1.55 |
| 2025-02-11 | -1.53 |
| 2025-02-10 | -1.59 |
| 2025-02-07 | -1.70 |